NovaBay Pharmaceuticals I... (NBY)
0.65
-0.06 (-8.58%)
At close: Jan 15, 2025, 1:55 PM
undefined% (undefined)
| Bid | 0.65 |
| Market Cap | 3.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -74.61 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.7 |
| Volume | 71,386 |
| Avg. Volume (20D) | 569,844 |
| Open | 0.70 |
| Previous Close | 0.71 |
| Day's Range | 0.65 - 0.71 |
| 52-Week Range | 0.36 - 9.10 |
| Beta | undefined |
About NBY
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 26, 2007
Employees 24
Stock Exchange AMEX
Ticker Symbol NBY
Website https://novabay.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NBY stock is "Buy." The 12-month stock price forecast is $0.85, which is an increase of 30.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
NovaBay Pharmaceuticals Inc. is scheduled to release its earnings on Mar 25, 2025,
during market hours.
Analysts project revenue of $2.50M, reflecting a -32.92% YoY shrinking and earnings per share of -0.24, making a -96.73% decrease YoY.
Analysts project revenue of $2.50M, reflecting a -32.92% YoY shrinking and earnings per share of -0.24, making a -96.73% decrease YoY.
2 months ago ·
Source
+18.24%
NovaBay Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 months ago ·
Source
+48.92%
NovaBay Pharmaceuticals shares are trading higher after the company announced it reached a definitive deal to sell its Avenova assets for $9.5 million.
